<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163395</url>
  </required_header>
  <id_info>
    <org_study_id>CR 01/07</org_study_id>
    <nct_id>NCT02163395</nct_id>
  </id_info>
  <brief_title>Performance Evaluation of FullCeram Implants in Single Tooth Gaps</brief_title>
  <official_title>A Prospective Open Label Single Arm Study to Evaluate the Performance of Straumann Monotype FullCeram (Zirconium Dioxide) Implants in Single Tooth Gaps in the Maxilla and Mandible</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Straumann AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Straumann AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Straumann Monotype FullCeram implants serve as a suitable alternative for implant
           therapy especially in the aesthetic zone

        -  The survival rate of Straumann Ceramic implants should be at least 85% (max 6 implant
           losses out of 40 patients) after the first year
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open label, single arm, multicenter study. The total study duration
      for each patient should be 35 to 42 month including a 3-year follow-up). It is acceptable to
      have the visit performed up to 6 month after the aspired date.

      The primary study parameter will be analyzed as soon as every patient passed visit 6 (annual
      follow-up visit, 12 month +/- 4 weeks).

      Implants will be placed transmucosally and will be protected by a thermoplastic splint for
      healing. A provisional prosthesis will be placed (out of occlusion) 12-14 weeks post implant
      placement. The final crown will be done between study week 24 and 28. Implant srvival,
      implant success, bone loss, periodontal parameters and adverse events will be assessed in the
      follow-up visits.

      In total 8 visits are scheduled in this study. The investigational device: Straumann
      FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths
      of 8, 10, 12 and 14 mm and abutment heights of 4.0 or 5.5 mm. This is a CE marked product.

      Three centres in Germany will participate. The study and any amendments will be performed as
      far as possible according to ISO 14155 (Second Edition, 2011-02-01) and conform to the
      Declaration of Helsinki (last revised Seoul 2008) and local legal and regulatory
      requirements.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Implant Survival</measure>
    <time_frame>Measured at 12 months +/- 4 weeks after implant placement</time_frame>
    <description>A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Implant Success</measure>
    <time_frame>Measured at Week 26, Month 12, Month 24 and Month 36</time_frame>
    <description>According to Buser et al 1992 an implant will be deemed a success if all of the following success criteria apply.
Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation)
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics)
Absence of implant mobility on manual palpation
Absence of any continuous peri-implant radiolucency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Bone Level Changes (Distal and Mesial)</measure>
    <time_frame>Measured at Week 26, Month 12, Month 24 and Month 36</time_frame>
    <description>A radiographic stent was produced to have a standard measurement. The distal and mesial bone levels were combined into a single value by averaging the two values. Negative bone level changes representing bone loss between baseline and follow-up visits, vice versa positive changes representing bone gain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Implant Survival</measure>
    <time_frame>Measured at Week 26, Month 24 and Month 36</time_frame>
    <description>A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Tooth Loss</condition>
  <arm_group>
    <arm_group_label>FullCeram implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FullCeram implant</intervention_name>
    <description>FullCeram implantation</description>
    <arm_group_label>FullCeram implant</arm_group_label>
    <other_name>Straumann Monotype FullCeram (Zirconium dioxide)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have voluntary signed the informed consent and the data protection
             consent form before any study related action

          -  Males and females with at least 18 years of age (including 18 years)

          -  Implant placement planned in the maxilla or mandible

          -  The missing tooth site must have a tooth with a natural root

          -  Substantially healed and augmented extraction sockets (minimal 8 weeks)

          -  Autogenous bone augmentation until 3 month pre-implantation were bone deficiency
             jeopardizing the implant position

        Exclusion Criteria:

        Pre-surgical exclusion criteria:

          -  Systemic disease that would interfere with dental implant therapy

          -  Any contraindications for oral surgical procedures

          -  Mucosal diseases

          -  History of local irradiation therapy

          -  Current untreated periodontitis or gingivitis

          -  Any untreated endodontic lesions

          -  Probing pocket depth of &gt; or = 4 mm on one of the teeth immediately adjacent to the
             dental implant site

          -  Severe bruxing or clenching habits

          -  Patients with inadequate oral hygiene or unmotivated for adequate home care

          -  Patients who smoke &gt;10 cigarettes per day or tobacco equivalents or chew tobaco

          -  Subjects who have undergone administration of any investigational device within 30
             days of enrolment in the study

          -  Conditions or circumstances, in the opinion of the investigator, which would prevent
             completion of study participation or interfere with analysis of study results, such as
             history of non-compliance or unreliability

          -  Physical or mental handicaps that would interfere with the ability to perform adequate
             oral hygiene

          -  Pregnant women at screening

        Secondary exclusion criteria at or after implant surgery:

          -  Lack of primary stability of the implant (hand testing directly after surgery)

          -  Inappropriate implant position for the prosthetic requirements (to be estimated before
             provisional restoration)

          -  Major simultaneous augmentation procedures (at surgery)

          -  X-ray of implant does not show the implant from first bone contact to apical tip (at
             surgery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Weingart, Prof Dr Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katharinenhospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover Klinik und Poliklinik fuer Mund-, Kiefer- und Gesichtschirurgie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice Theatinerstrasse 1</name>
      <address>
        <city>Munich</city>
        <zip>80333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Lambrecht TJ, Filipi A, Raetzer Luenzel A, Schiel HJ. Long-Term evaluation of submerged and nonsubmerged ITI solid-screw titanium implants. A 10-year life table analysis of 468 implants. Int J Oral Maxifollofac Implants; 18:826-834, 2003. Kohal R J, et al. Loaded custom-made zirconia and titanium implants show similar osseointegration: an animal experiment. J Periodontol. 75.9, 1262-68, 2004. Scarano A, et al. Bone response to zirconia ceramic implants: an experimental study in rabbits. J Oral Implantol. 8-12, 29.1, 2003. Sennerby L, at al. Bone tissue resonses to surface-modified zirconia implants: A histomorphometric and removal torque study in the rabbit. Clin. Implant. Dent.Relat Res. 7 Suppl: S13-S20, 2005. Blaschke C, and Volz U. Soft and hard tissue response to zirconium dioxide dental implants - a clinical study in man. Neuro.Endocrinol.Lett. 27.Suppl1, 2006. Olivia J, Olivia X, Olivia JD. One year follow-up of first consecutive 100 Zirconia Dental Implants in humans: A comparison of 2 different rough surfaces. Int J Oral Maxillofac Implants; 22:430-435, 2007. Herrmann JS, Buser D, Schenk RK, Schoolfield JD, Cochran DL. Biologic width around one-and two-piece titanium implants. A histometric evaluation of unloaded nonsubmerged and submerged implants in the canine mandible. Clin Oral Impl Res 12, 559-571, 2001. Todescan FF, Pustiglioni FE, Imbronito AV, Albrektson T, Gioso M. Influenze of the microgap in the peri-implant hard and soft tissues. A histomorphometric study in dogs. Int J Pral Maxillofac Implants 17:467-472, 2002. Buser D, Weber HP, Braegger U, Balsinger C. Gewebeintegration einphasiger ITI-Implantate: Drei-Jahres-Ergebnisse einer prospektiven Langzeitstudie mit Hohlzylinder- und Hohlschraubenimplantaten. Buser D, Martin W, Belser UC. Optimizing Esthetics for Implant restorations in the Anterior Maxilla: Anatomic and Surgical Considerations. Int. J Oral and Maxillofacial Implants. Supplement; 19:43-61, 2004.</citation>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <results_first_submitted>May 18, 2015</results_first_submitted>
  <results_first_submitted_qc>July 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <last_update_submitted>May 29, 2017</last_update_submitted>
  <last_update_submitted_qc>May 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ceramic implant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tooth Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FullCeram Implant</title>
          <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
FullCeram implant: FullCeram implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FullCeram Implant</title>
          <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
FullCeram implant: FullCeram implantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Implant Survival</title>
        <description>A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.</description>
        <time_frame>Measured at 12 months +/- 4 weeks after implant placement</time_frame>
        <population>Implant survival rates provided for the patients of the ITT population, who had valid data. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>FullCeram Implant</title>
            <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
FullCeram implant: FullCeram implantation</description>
          </group>
        </group_list>
        <measure>
          <title>The Implant Survival</title>
          <description>A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.</description>
          <population>Implant survival rates provided for the patients of the ITT population, who had valid data. Missing data were not imputed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="86.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Implant Success</title>
        <description>According to Buser et al 1992 an implant will be deemed a success if all of the following success criteria apply.
Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation)
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics)
Absence of implant mobility on manual palpation
Absence of any continuous peri-implant radiolucency</description>
        <time_frame>Measured at Week 26, Month 12, Month 24 and Month 36</time_frame>
        <population>Implant success rates provided for the patients of the ITT population, who had valid data. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>FullCeram Implant</title>
            <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
FullCeram implant: FullCeram implantation</description>
          </group>
        </group_list>
        <measure>
          <title>The Implant Success</title>
          <description>According to Buser et al 1992 an implant will be deemed a success if all of the following success criteria apply.
Absence of persisting subjective discomfort such as pain, foreign body perception and or dysaesthesia (painful sensation)
Absence of a recurrent peri-implant infection with suppuration (where an infection is termed recurrent if it is observed at two or more follow-up visits after treatment with systemic antibiotics)
Absence of implant mobility on manual palpation
Absence of any continuous peri-implant radiolucency</description>
          <population>Implant success rates provided for the patients of the ITT population, who had valid data. Missing data were not imputed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 (n=43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="80.7" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="86.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1" lower_limit="83.0" upper_limit="99.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="86.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Bone Level Changes (Distal and Mesial)</title>
        <description>A radiographic stent was produced to have a standard measurement. The distal and mesial bone levels were combined into a single value by averaging the two values. Negative bone level changes representing bone loss between baseline and follow-up visits, vice versa positive changes representing bone gain.</description>
        <time_frame>Measured at Week 26, Month 12, Month 24 and Month 36</time_frame>
        <population>Standardised bone level measurements provided for the ITT population. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>FullCeram Implant</title>
            <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
FullCeram implant: FullCeram implantation</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Bone Level Changes (Distal and Mesial)</title>
          <description>A radiographic stent was produced to have a standard measurement. The distal and mesial bone levels were combined into a single value by averaging the two values. Negative bone level changes representing bone loss between baseline and follow-up visits, vice versa positive changes representing bone gain.</description>
          <population>Standardised bone level measurements provided for the ITT population. Missing data were not imputed.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n=37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Implant Survival</title>
        <description>A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.</description>
        <time_frame>Measured at Week 26, Month 24 and Month 36</time_frame>
        <population>Implant survival rates provided for the patients of the ITT population, who had valid data. Missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>FullCeram Implant</title>
            <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
FullCeram implant: FullCeram implantation</description>
          </group>
        </group_list>
        <measure>
          <title>The Implant Survival</title>
          <description>A surviving implant is an integrated implant in the patient's jaw bone at the time of assessment.</description>
          <population>Implant survival rates provided for the patients of the ITT population, who had valid data. Missing data were not imputed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26 (n= 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="86.6" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n= 41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6" lower_limit="86.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 (n= 40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="86.0" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AE) were reported from the time a patient provided written informed consent to the 36-month follow-up visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FullCeram Implant</title>
          <description>Straumann FullCeram Implant is a monotype ZrO2 implant with a diameter of 4.1 mm, available in lengths of 8, 10, 12 and 14 mm and abutment hights of 4.0 or 5.5 mm
FullCeram implant: FullCeram implantation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Meniscus surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Calcaneal spur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Birth of a boy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <description>not related</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Thyroid hypofunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pocket formation and bone loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cold, influenza or sore throat</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Chronic bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease of gingiva</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding, swelling, inflammation / infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Insufficient, loose or broken crown</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Implant success criteria not fulfilled</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Intsitut Straumann AG</name_or_title>
      <organization>Clinical Research</organization>
      <phone>0041619651111</phone>
      <email>research@straumann.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

